AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 APR 2 - (NewsRx.com & NewsRx.net) -- The only clinical trial for an experimental Alzheimer disease (AD) vaccine was halted last year when 15 of the trial participants developed severe brain inflammation. Now James Nicoll and colleagues have presented the first analysis of the vaccine's effects on the human brain.
In the U.S. alone, AD affects nearly 4 million people, and the number is expected to triple in the next 30 years. The brain of an AD patient is characterized by tangled bundles of nerve fibers and amyloid "plaques" - clusters of a sticky protein called amyloid-beta. In mice, a vaccine directed against the amyloid-beta peptide clears the plaques and alleviates the memory ...